In this long-term follow-up to the phase 2 ARTO trial, researchers analyzed survival outcomes in patients with CRPC treated with metastasis-directed therapy.

Figure 3: Immunohistochemistry (IHC) and Immunofluorescence (IF) analysis of MD2 expression and immune cell infiltration in prostate cancer tissues. (Upper panel) Representative IF images showing ...

Impact of androgen receptor pathway inhibitor (ARPI) dose reduction on overall survival of metastatic castration-resistant prostate cancer: A multi-centre retrospective study.

New findings out of VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM)—published in Pharmacological Research, ranked among the top pharmacology journals globally ...

Cell-free DNA nucleosome and genomic signatures as predictors of outcomes with radium-223 in metastatic castration-resistant prostate cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Annual ...

Bone metastases represent a common and debilitating stage in the progression of many solid tumours, notably breast, prostate and lung cancers. Tumour cells that home to the skeleton disrupt the normal ...

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...